Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ICO 007

Drug Profile

ICO 007

Alternative Names: ICO-007; ISIS-13650

Latest Information Update: 04 Dec 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer iCo Therapeutics; JDRF
  • Class Antisense oligonucleotides; Eye disorder therapies
  • Mechanism of Action Proto oncogene proteins c raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Discontinued Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 28 Nov 2014 ICO 007 is available for licensing as of 28 Nov 2014. www.icotherapeutics.com/
  • 28 Nov 2014 Discontinued - Phase-II for Diabetic macular oedema in USA (Intravitreous)
  • 28 Nov 2014 Discontinued - Preclinical for Age-related macular degeneration in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top